The Path Forward for Psychedelic Assisted Psychotherapy Investor Presentation July 2020 Our Mission

To bring the world to life through psychedelics and psychedelic enhanced psychotherapy.

Mental health conditions are on the rise.

Rapid Growth. Limited Treatments.

+2 Current treatments haven’t Point improvement on Hamilton changed in decades Depression Score (out of 52) and have proven to be ineffective with 40-71% undesired side-effects Relapse rates

Side Effects Addiction, Insomnia, Agitation, Loss of Libido, Violent Impulses, Suicidal Impulses

1. Star*D Study

Evidence for Psychedelic Therapies

For depression For addiction For general well-being Extended relief from Addiction decreases after Sustained improvement in quality depression >3months psilocybin treatment oflife and satisfaction

75 40 Severe days First psilocybin treatment following depression week 4 assessments

drinking participants

Mo d e r a t e 50 of

depression of (%) (%) 20 (%)

Mild depression

25 Percent 10 Percent

Before 1 2 3 5 3 Weeks Weeks Weeks Weeks Weeks 2 months after 2 months 14 months treatment W eek Weeks Weeks Weeks Months 1-4 5-6 9-12 13-24 25-36 methylphenidate after after treatment psilocybin psilocybin (control) treatment treatment

Source: Psilocybin with Psychological Support for Treatment Resistant Source: Psilocybin-assisted treatment for alcohol dependence: Source: Psilocybin-occasioned mystical-type experience in combination with Depression, R. Carhart-Harris, The Lancet A proof- ofconcept study, M. Bogenshutz, Journal of Psychopharmacology meditation [...] R. Griffiths, Journal of Psychopharmacology

Compared to other drugs, psychedelics have a low harm profile

$16B Anxiety Disorder $38B & Botanical Supplements Depression Treatment Market 2 Market 1 $10B Illustrative Adult Use Market 3 *Sour1Source: Global Newswire, Reports and Data, May 2019 2Source: ”Botanical Supplements Market Size and Forecast, Hexa Research September 20183Estimated at % of global cannabis market based on relative proportion of use. Global Newswire, Reports and Data, May 2019. ©2020 Core One Labs **Source: US Substance Abuse and Mental Health Administration (SAMHSA) 7 Our Strategy

We are pursuing the development and commercialization of rapid onset treatments capable of improving health outcomes. Our first product is CannaStrips which we will aim to use as a delivery tool for cannabis and psychedelic treatments.

We will achieve this through R&D and Clinical Trials at the University of British Columbia. We offer a fully operational Clinic in British Columbia with 8 years of operating history. The Clinic provides training and education for medical professionals interested in psychedelic assisted psychotherapy and psychedelic integration psychotherapy.

Leveraging its existing SOPs, data driven research sets and practitioner education modules, we will roll out Clinics across Canada. ©2020 Core One Labs 8 How Our Solution Works: Using psychedelic molecules to catalyze the efficacy of psychotherapy is showing great promise

Psychedelic Assisted Psychotherapy

Treatment Sessions Integration Therapy On-Going Care

Approval of the treatment plan Psychotherapists will help your patient Typical treatment is 6 dosing sessions First dosing session integrate the experiences using with 3 integration sessions. Licensed psychotherapist, immediately different clinical psychology techniques Patients will also have access to our following the dosing session, provide Drive habit change and outlook/mindset digital patient portal for on-going exploratory therapy. improvements. support and education to help sustain Dosing sessions are typically the effects of the KAP. scheduled 2-3 days apart.

Treatment-Resistant Depression (TRD)

Addiction

PTSD/Brain Injury

Aging/Dementia

Anxiety/Obsessive-Compulsive Indications for Clinical Treatment Rollout Disorder (OCD)

Offer specialty therapy as a complementary, follow-on service

Naturopathic Clinician

Psychologist

Cognitive and Psychodynamic Psychotherapists

Family Therapist

Adult Psychiatrist

CannaStrips™, a precisely dosed edible polymer delivery strip similar to a breath strip.

Placed under the tongue CannaStrips™ deliver the active ingredient (functional mushrooms, Psilocybin THC, CBD, others) directly into circulation.

Avoids imprecise dosing and first-pass metabolism in the liver inherent with ingested products.

CannaStrips™ offer an effective dosage with no degradation of the liver. The result is a consistent, precise, and effective experience.

Core One Labs has control of all stages of production, distribution, transportation and delivery of CannaStrips™.

Our therapy will use regulated dosages of psychedelic compounds like ketamine and psilocybin in a safe, fully supervised setting. The treatment will be used alongside psychotherapy.

These lower doses can promote better mental health by disrupting thought patterns or loops that may be preventing progress.

The experience has been described as ”euphoric,” “calming,” and “mystical.”

Integrated Intellectual Valuation Clinics Focus Molecule Model Property (CAD) Psilocybin, Delivery Core One Labs Yes Multi $45MM Ketamine, THC Technology Mydecine Yes Clinic Psilocybin $140MM Innovations Group

MindMed No Drug Development 18-MC, LSD Phase 1, Phase 2 $145MM

Psilocybin Psilocybin, Numinus Yes Multi cultivation and $30MM Ketamine extraction license Delivery Cybin Yes Multi Psilocybin $60MM Technology Champignon Yes Multi Psilocybin+CBD Pre-clinical $150MM Brands Ketamine, FT- Field Trip Yes Multi Ft-104 molecule $69MM 104

ATAI (Perception, Drug Arketamine, No Unknown $312MM DemeRx) Development Ibogaine

As of Date to May 20, 2020 *estimated valuation

Core One Labs 68,000,0001

Price $0.66

Market Cap $44,800,000

Cash $4,000,000

Assets $20,500,00

1. Post-acquisition of Shacor and Rejuva